Merck brings contract sales reps onboard

Share this article:
Merck announced a strategic partnership with inVentiv Health, whereby Merck will utilize inVentiv's contract sales staff to supplement Merck's in-house sales force.

The move comes in the wake of Merck's elimination of 15% of its U.S. sales force (1,200 jobs) four months ago.

According to a Dow Jones Newswire report, Whitehouse Station, NJ-based Merck, rather than recruit, hire or keep full-time representatives on the books, has decided to create a more flexible approach so as the market demands change, Merck can expand and contract the number of reps that is has at its disposal.

Merck didn't reveal how many inVentiv reps will be recruited or which drugs they'll be promoting. However, according to the Dow Jones report, the partnership does not include vaccines or drugs marketed to oncologists, ophthalmologists, or dermatologists.

InVentiv's Marcia Frederick said the company is seeing an upswing in its contract sales force business.

Separately, InVentiv announced that it has ended a contract with Boehringer Ingelheim, while initiating nine new sales team agreements including Merck.


Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...